Uprooting cancer: Hydrogel rapidly reverts cancer cells back to cancer stem cells

A hydrogel developed at Hokkaido University successfully reverted cancer cells back to cancer stem cells within 24 hours in six different human cancer types. This could lead to the development of anti

Updated on: November 02,2023 10

Uprooting cancer: Hydrogel rapidly reverts cancer cells back to cancer stem cells

A hydrogel developed at Hokkaido University successfully reverted cancer cells back to cancer stem cells within 24 hours in six different human cancer types. This could lead to the development of anti

Updated on:November 02,2023 10

Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on: July 06,2024 0

Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on:July 06,2024 0

New factor in the development of hereditary kidney cancer discovered

by Gabriele Meseg-Rutzen,University of CologneHira-andFh1-deficient cells promote tumor initiation, growth, and invasion in vivo.(A) Scheme of xenograft injections in the flank of nu

Updated on: December 21,2023 10

New factor in the development of hereditary kidney cancer discovered

by Gabriele Meseg-Rutzen,University of CologneHira-andFh1-deficient cells promote tumor initiation, growth, and invasion in vivo.(A) Scheme of xenograft injections in the flank of nu

Updated on:December 21,2023 10

Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local re

Updated on: December 19,2023 10

Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local re

Updated on:December 19,2023 10

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on: December 17,2023 10

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on:December 17,2023 10

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on: October 15,2023 142

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on:October 15,2023 142

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on: October 30,2023 26

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on:October 30,2023 26

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023 25

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023 25

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on: December 21,2023 10

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on:December 21,2023 10

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on: November 02,2023 10

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on:November 02,2023 10

How a patient partnership is propelling cancer research

by Leah Eisenstadt,Broad Institute of MIT and HarvardCount Me In Director Nikhil Wagle and Strategic Advisor Corrie Painter. Credit: Broad Institute of MIT and HarvardIn the fall of 2018, cancer

Updated on: December 19,2023 12

How a patient partnership is propelling cancer research

by Leah Eisenstadt,Broad Institute of MIT and HarvardCount Me In Director Nikhil Wagle and Strategic Advisor Corrie Painter. Credit: Broad Institute of MIT and HarvardIn the fall of 2018, cancer

Updated on:December 19,2023 12

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on: October 17,2023 240

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on:October 17,2023 240